Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow which is
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …

Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …

This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia
(AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly …

Dendritic cell (DC) vaccines induce specific immune responses that can selectively
eliminate target cells. In recent years, many studies have been conducted to explore DC …

Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days
of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason …

Research into the underlying pathogenic mechanisms of acute myeloid leukemia (AML) has
led to remarkable advances in our understanding of the disease. Mutations now allow us to …

Purpose We investigated the effect on outcome of measurable or minimal residual disease
(MRD) status after each induction course to evaluate the extent of its predictive value for …

The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is
widely overexpressed in various hematological malignancies, including acute myeloid …

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …

The contribution and role of circular RNAs (circRNAs) in mediating chemoresistance in
acute myeloid leukemia (AML) are still poorly understood and need further investigation. In …